New England Journal of Medicine Publishes Data From Durata Therapeutics ...
Wall Street Journal
CHICAGO, June 4, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ...
Easy-to-Use IV Antibiotics Could Help Treat Serious Skin InfectionsU.S. News & World Report

all 15 news articles »


More...